Showing results (61-70 of 41,938) with videos related to
Sort By:
Pageof 4,194
Fortschritte Der Neurologie-Psychiatrie|August 18, 2009
[Disciplinary differentiation under socialist conditions--the establishment of neurology at the University of Rostock in East Germany]E Kumbier, K Haack, U K ZettlScience (New York, N.Y.)|March 28, 1997
Single-Electron Transport in Ropes of Carbon NanotubesBockrath, Cobden, McEuen, et al.European Neurology|February 15, 2014
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityPeter Flachenecker, Thomas Henze, Uwe K ZettlPlos One|August 14, 2013
Headaches in multiple sclerosis patients might imply an inflammatorial processJan Möhrke, Peter Kropp, Uwe K ZettlCurrent Pharmaceutical Design|March 4, 2010
Autoantibodies in autoimmune diseasesM Eggert, U K Zettl, G NeeckEuropean Neurology|June 20, 2014
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practicePeter Flachenecker, Thomas Henze, Uwe K ZettlPharmaceutics|January 26, 2024
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple SclerosisMichael Hecker, Niklas Frahm, Uwe Klaus ZettlActa Neurologica Scandinavica|November 22, 2013
Spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of lifeP Flachenecker, T Henze, U K ZettlArchiv Der Pharmazie|November 27, 2010
Functionalization of fatty acid mimetics for solid-phase coupling and subsequent target identificationMichaela Dittrich, Heiko Zettl, Manfred Schubert-ZsilaveczAutoimmunity Reviews|June 14, 2015
Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patientsBrit Fitzner, Michael Hecker, Uwe Klaus ZettlPageof 4,194